Erratum to

Plant-derived immunomodulators: An insight on their preclinical evaluation and clinical trials (Frontiers in Plant Science, (2015), 6, 10.3389/fpls.2015.00655)

Research output: Contribution to journalComment/debate

Abstract

In the original article “Fürst and Zündoft, 2014” was not cited in the article. The citation has now been inserted in section Immunomodulators, Paragraph 3 and should read: “Recently the clinical potential of six plant-derived anti-inflammatory compounds: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate (EGCG), and quercetin has been highlighted Fürst and Zündoft (2014). The present review will give an overview of these widely investigated plant-derived compounds including andrographolide and genistein, which have exhibited potent effects on cellular and humoral immune functions in pre-clinical investigations and will highlight their clinical potential.” The citation has now been inserted in section Curcumin, Paragraph 2 and should read: “However, Fürst and Zündoft (2014) suggested that these are preliminary clinical trials which are frequently too weak and of low quality to draw a conclusion due to the low number of enrolled patients, which normally ranges from 10 to 30. As suggested by the authors, more operationally thorough and serious randomized controlled trials are required to evaluate the compound as an effective and safe agent for human use. It is worth mentioning that curcumin suffers from its low bioavailability, though substantial improvement has been made to address this issue via chemical and technological methods (Anand et al., 2007).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original languageEnglish
Article number1178
JournalFrontiers in Plant Science
Volume9
DOIs
Publication statusPublished - 13 Aug 2018

Fingerprint

immunomodulators
curcumin
clinical trials
capsaicin
epigallocatechin
resveratrol
genistein
colchicine
quercetin
bioavailability
methodology

Keywords

  • Capsaicin
  • Colchicine
  • Curcumin
  • Epigallocatechol-3-gallate
  • Immunomodulation
  • Quercetin
  • Resveratrol

ASJC Scopus subject areas

  • Plant Science

Cite this

@article{699ab4242ef44349aecc1183975eadf1,
title = "Erratum to: Plant-derived immunomodulators: An insight on their preclinical evaluation and clinical trials (Frontiers in Plant Science, (2015), 6, 10.3389/fpls.2015.00655)",
abstract = "In the original article “F{\"u}rst and Z{\"u}ndoft, 2014” was not cited in the article. The citation has now been inserted in section Immunomodulators, Paragraph 3 and should read: “Recently the clinical potential of six plant-derived anti-inflammatory compounds: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate (EGCG), and quercetin has been highlighted F{\"u}rst and Z{\"u}ndoft (2014). The present review will give an overview of these widely investigated plant-derived compounds including andrographolide and genistein, which have exhibited potent effects on cellular and humoral immune functions in pre-clinical investigations and will highlight their clinical potential.” The citation has now been inserted in section Curcumin, Paragraph 2 and should read: “However, F{\"u}rst and Z{\"u}ndoft (2014) suggested that these are preliminary clinical trials which are frequently too weak and of low quality to draw a conclusion due to the low number of enrolled patients, which normally ranges from 10 to 30. As suggested by the authors, more operationally thorough and serious randomized controlled trials are required to evaluate the compound as an effective and safe agent for human use. It is worth mentioning that curcumin suffers from its low bioavailability, though substantial improvement has been made to address this issue via chemical and technological methods (Anand et al., 2007).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.",
keywords = "Capsaicin, Colchicine, Curcumin, Epigallocatechol-3-gallate, Immunomodulation, Quercetin, Resveratrol",
author = "Ibrahim Jantan and Waqas Ahmad and {Syed Nasir Abbas}, Bukhari",
year = "2018",
month = "8",
day = "13",
doi = "10.3389/fpls.2018.01178",
language = "English",
volume = "9",
journal = "Frontiers in Plant Science",
issn = "1664-462X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Erratum to

T2 - Plant-derived immunomodulators: An insight on their preclinical evaluation and clinical trials (Frontiers in Plant Science, (2015), 6, 10.3389/fpls.2015.00655)

AU - Jantan, Ibrahim

AU - Ahmad, Waqas

AU - Syed Nasir Abbas, Bukhari

PY - 2018/8/13

Y1 - 2018/8/13

N2 - In the original article “Fürst and Zündoft, 2014” was not cited in the article. The citation has now been inserted in section Immunomodulators, Paragraph 3 and should read: “Recently the clinical potential of six plant-derived anti-inflammatory compounds: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate (EGCG), and quercetin has been highlighted Fürst and Zündoft (2014). The present review will give an overview of these widely investigated plant-derived compounds including andrographolide and genistein, which have exhibited potent effects on cellular and humoral immune functions in pre-clinical investigations and will highlight their clinical potential.” The citation has now been inserted in section Curcumin, Paragraph 2 and should read: “However, Fürst and Zündoft (2014) suggested that these are preliminary clinical trials which are frequently too weak and of low quality to draw a conclusion due to the low number of enrolled patients, which normally ranges from 10 to 30. As suggested by the authors, more operationally thorough and serious randomized controlled trials are required to evaluate the compound as an effective and safe agent for human use. It is worth mentioning that curcumin suffers from its low bioavailability, though substantial improvement has been made to address this issue via chemical and technological methods (Anand et al., 2007).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

AB - In the original article “Fürst and Zündoft, 2014” was not cited in the article. The citation has now been inserted in section Immunomodulators, Paragraph 3 and should read: “Recently the clinical potential of six plant-derived anti-inflammatory compounds: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate (EGCG), and quercetin has been highlighted Fürst and Zündoft (2014). The present review will give an overview of these widely investigated plant-derived compounds including andrographolide and genistein, which have exhibited potent effects on cellular and humoral immune functions in pre-clinical investigations and will highlight their clinical potential.” The citation has now been inserted in section Curcumin, Paragraph 2 and should read: “However, Fürst and Zündoft (2014) suggested that these are preliminary clinical trials which are frequently too weak and of low quality to draw a conclusion due to the low number of enrolled patients, which normally ranges from 10 to 30. As suggested by the authors, more operationally thorough and serious randomized controlled trials are required to evaluate the compound as an effective and safe agent for human use. It is worth mentioning that curcumin suffers from its low bioavailability, though substantial improvement has been made to address this issue via chemical and technological methods (Anand et al., 2007).” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

KW - Capsaicin

KW - Colchicine

KW - Curcumin

KW - Epigallocatechol-3-gallate

KW - Immunomodulation

KW - Quercetin

KW - Resveratrol

UR - http://www.scopus.com/inward/record.url?scp=85054548402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054548402&partnerID=8YFLogxK

U2 - 10.3389/fpls.2018.01178

DO - 10.3389/fpls.2018.01178

M3 - Comment/debate

VL - 9

JO - Frontiers in Plant Science

JF - Frontiers in Plant Science

SN - 1664-462X

M1 - 1178

ER -